Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)

Diabetes Care - United States
doi 10.2337/dc13-2759
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Diabetes Association

Related search

Efficacy and Safety of Diacerein in Patients With Inadequately Controlled Type 2 Diabetes: A Randomized Controlled Trial

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2017English

Efficacy and Safety of Dulaglutide in the Treatment of Type 2 Diabetes: A Comprehensive Review of the Dulaglutide Clinical Data Focusing on the AWARD Phase 3 Clinical Trial Program

Diabetes/Metabolism Research and Reviews
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Comparative Efficacy of Glimepiride and Metformin in Monotherapy of Type 2 Diabetes Mellitus: Meta-Analysis of Randomized Controlled Trials

Diabetology and Metabolic Syndrome
Internal MedicineEndocrinologyMetabolismDiabetes
2013English

A Phase 3 Randomized Placebo-Controlled Trial to Assess the Efficacy and Safety of Ipragliflozin as an Add-On Therapy to Metformin in Russian Patients With Inadequately Controlled Type 2 Diabetes Mellitus

Diabetes Research and Clinical Practice
Internal MedicineEndocrinologyMetabolismMedicineDiabetes
2018English

Efficacy and Safety of Liraglutide Versus Sitagliptin, Both in Combination With Metformin, in Chinese Patients With Type 2 Diabetes: A 26-Week, Open-Label, Randomized, Active Comparator Clinical Trial

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of Hydroxychloroquine in Patients With Type 2 Diabetes Mellitus

Global Journal of Endocrinological Metabolism
2018English

Efficacy and Safety of Once-Weekly Semaglutide Monotherapy Versus Placebo in Patients With Type 2 Diabetes (SUSTAIN 1): A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group, Multinational, Multicentre Phase 3a Trial

The Lancet Diabetes and Endocrinology
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

Efficacy and Safety of Once-Weekly Semaglutide Versus Daily Canagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes (SUSTAIN 8): A Double-Blind, Phase 3b, Randomised Controlled Trial

The Lancet Diabetes and Endocrinology
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Walking Away From Type 2 Diabetes: A Cluster Randomized Controlled Trial

Diabetic Medicine
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy